The Medical Letter on Drugs and Therapeutics
Mavyret and Vosevi - Two New Combinations for Chronic HCV Infection
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved Mavyret (Abbvie) and Vosevi (Gilead), two new fixed-dose combinations of direct-acting antiviral (DAA) drugs, for treatment of chronic hepatitis C virus (HCV) infection caused by any of the six major HCV genotypes in patients without cirrhosis or with compensated cirrhosis. Both are approved for use in treatment-experienced patients. Mavyret is also approved for treatment-naive patients.

HCV GENOTYPES — HCV genotype 1 accounts for about 75% of HCV infections in the US, genotypes 2 and 3 account for about 20-25% of infections, genotype 4 for about 6%, and genotypes 5 and 6 for ≤1%. Genotype testing is recommended to determine the optimal treatment regimen.

TREATMENT OPTIONS FOR DAA-EXPERIENCED PATIENTS — Treatment of chronic HCV infection with DAAs results in sustained virologic response (SVR) rates of >90% in treatment-naive patients and ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Mavyret and Vosevi - Two New Combinations for Chronic HCV Infection
Article code: 1531b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian